Déséquilibre glycémique lors du diagnostic d’un myélome multiple révélant un diabète de type 1 à anticorps anti-GAD : une association fortuite ?
C. Nivet(Institut universitaire du cancer de Toulouse Oncopole), S. Ollier(Institut universitaire du cancer de Toulouse Oncopole), K. Delavigne(Human Technopole), C. Nozal(Institut universitaire du cancer de Toulouse Oncopole), Thibault Comont(Institut universitaire du cancer de Toulouse Oncopole), C Pierre(Institut universitaire du cancer de Toulouse Oncopole), Julien Maquet(Hôpital Purpan), Odile Beyne‐Rauzy(Université Paris-Sud), M. Lemeu(Institut universitaire du cancer de Toulouse Oncopole)
Cited by 0
Related Papers
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
|Leukemia|2011|464
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience
|Blood|2007|332
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)
|Blood|2009|270
Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults
|Journal of Thrombosis and Haemostasis|2018|138